Par Sues UCB Over Generic Keppra
Par Pharmaceutical Cos. Inc. filed suit Wednesday in Pennsylvania seeking declaratory judgment that its proposed generic version of epilepsy treatment Keppra XR doesn't infringe UCB Pharma SA's patents covering the drug....To view the full article, register now.
Already a subscriber? Click here to view full article